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Dengue virus (DENV) is the most important viral pathogen transmitted by 
Aedes sp. mosquitoes and the causative agent of dengue fever. According to 
WHO, over 40% of the world population is at risk from dengue and about 2.5% 
of those affected die each year. Our laboratory has previously identified a novel 
bacterium in the gut of field caught Aedes mosquitoes that had interesting 
properties with regards to vector competence. It was identified as 
Chromobacterium Panama (Csp_P), and studies have shown that it inhibit DENV 
infection in the mosquito. Further studies showed that the Csp_P culture 
supernatant could inhibit DENV infection in vitro. Based on these findings, we 
characterized several biochemical features and the mode of action of the 
putative anti-DENV factors. The Csp_P-derived anti-DENV factors were heat-
stable at 70°C and the activity was enriched in the protein fraction, with 
molecular weights ranging from 50-100kDa. The activity seems to be associated 
with a Csp_P secreted multiprotein complex or protein oligomer. We also 
documented an apparent loss of the DENV envelope protein upon exposure to 
this protein fraction, which most likely account for abolished viral attachment 
to host cells. Additionally, proteomic analysis of the fraction identified 33 
unique Csp_P proteins, including an extracellular cholesterol oxidase that has 
been indirectly linked to viral replication in several studies. Several bacterial 
metalloproteases were also identified, and may be responsible for the proteolytic 
degradation of the DENV envelope protein. Together, our study characterized an 
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Dengue virus (DENV) is a mosquito-borne, positive-sensed RNA virus 
belongs to the Flaviviridae family. The family also include the yellow fever, West 
Nile, Japanese encephalitis, tick born encephalitis, and Zika viruses (Blitvich & 
Firth, 2015). Infection with DENV often causes dengue fever (DF), which is 
characterized by biphasic fever, headache, pain in various parts of the body, 
rash, lymphadenophathy, and leukopenia (Lei et al., 2001). Therefore, the name 
of dengue was initially “dandy fever” based on symptoms of infected individuals 
during the West Indian epidemic of 1827 (Smart, 1877). In most cases, DENV is 
self-limited. However, there is a risk of progressive development (2-2.5% of the 
cases) into severe manifestations such as dengue hemorrhagic fever (DHF) or 
dengue shock syndrome (DSS) (Lei et al., 2001).  The disease is transmitted 
among humans via competent female Aedes mosquitoes, with Ae. aegypti being 
the primary vector, a cosmotropical mosquito that thrives in urban 
environments(Lam, 2013) (Bowman, Donegan, & McCall, 2016). According to 
the World Health Organization (WHO), approximately half of the world’s 
population is at risk of infection with DENV, along with 22,000 deaths occur 
each year mainly among children. The incidence of dengue has increased by 30-
fold over the last 50 years, and this is attributed largely to urbanization, global 
warming and international travels  (Abd Kadir, Yaakob, & Mohamed Zulkifli, 
2013). In general, dengue is prevalent in tropical and subtropical regions, 
disseminating in more than 100 endemic countries in the southeast Asia, the 
western Pacific, the Americas, the Middle East and Africa (Guzman & Harris, 
2015) (Figure 1). Currently, no therapeutics for dengue infection are available, 
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while clinical management remains supportive care (Anders & Hay, 2012). 
Nevertheless, nearly a half of patients with dengue have limited access to 
standard treatment (Lam, 2013). Until the recent advance in dengue vaccine 
development, dengue control has been solely relied on the control of its Aedes 
vectors, implying an unmet need for therapeutic interventions (Nedjadi et al., 
2015). My study focuses on a novel Chromobacterium. sp, bacterial strain 
(Csp_P) which produces metabolite(s) that reduce DENV replication in both 
mosquito and cell cultures (Ramirez et al., 2014).  
The global burden of dengue  
To date, it has been estimated that nearly 4 billion people worldwide are 
at risk of dengue infection, yet the incidence of dengue is underestimated and is 
continuously increasing (Brady et al., 2012). Increased global incidence of  
dengue is due to a number of factors, including the uncontrolled vector (the 
expanding range and population of the Aedes mosquito along with increased 
temperature and precipitation) and the amplified transmission dynamic (rapid 
population growth as a result of rural to urban migration, leading to 
uncontrolled urbanization, increasing international travel due to globalization, 
enabling infected human hosts to move the viruses long distances more) (Lam, 
2013). Unlike malaria, which is more prevalent in rural areas, cases of dengue 
are more common in urban and sub-urban areas. It is much more complicated 
to control dengue in highly populated areas in cities (Abd Kadir et al., 2013). 
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Challenges to effectively control dengue also attributed by the 
heterogeneous dengue serotype circulating. There are 4 antigenically and 
phylogenetically distinct but close-related  serotypes, DENV1-DENV4 
(Satterfield, Dawes, & Milligan, 2016). Infection with one serotype confers long-
term protective immunity against infecting serotype, and temporary immunity 
to the three other serotypes (Fibriansah et al., 2014) (Guzman & Harris, 2015). 
The postulated mechanism for secondary infections associated with severe 
disease has been established as antibody-dependent enhancement (ADE) 
(Diamond & Pierson, 2015). During a primary dengue infection, cross-reactive, 
poorly-neutralizing antibodies are generated. During the secondary infection 
with a different DENV serotype, the Fc portion of the cross-reactive antibodies 
can bind to virions and facilitate virus entry into FcR-bearing target cells 
(Botting & Kuhn, 2012) (Lau et al., 2015). Therefore, incomplete infection-
induced immunity failed to cover all four serotype theoretically could predispose 
an individual to severe disease during secondary infection (Diamond & Pierson, 
2015). Spatial patterns in concurrent and/or sequential circulation of DENV1–4 
should be considered as potentially important population-level risk factors for 





Figure 1. DENV co-circulation. Certain serotypes of DENV are prevalent in 
colored areas. Observation of potential increases in co-circulation of the four 
viruses, which may serve as a key indicator of progression toward 
hyperendemic transmission. (Messina et al., 2014) 
Current control measures 
At present, the major approach to control or prevent the transmission of 
DENV is to combat vector mosquitoes (WHO). Mosquitoes transmit the virus by 
first taking an infectious blood meal. Viruses within the blood are ingested in 
the mosquito midgut, infect and replicate in the midgut epithelial cells. As the 
progeny viruses are released into mosquito hemolymph they can reach and 
infect other organs, including the mosquito salivary glands. After 10–14 days 
post initial blood meal, viruses in the salivary glands can be inoculated to 
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another person through a subsequent blood meal, which completes the 
transmission cycle (Nedjadi et al., 2015). 
Currently, vector control efforts aim to reduce mosquito population 
density by targeting the immature aquatic stages or the adult stages (Bowman 
et al., 2016). Control efforts involve environmental, chemical and biological 
management approaches. Environmental modification or sanitation 
improvements require a continuous effort. The effectiveness of these 
interventions is often impaired by interruption due to insufficient financing to 
maintain infrastructures (Anders & Hay, 2012). Additionally, the use of 
traditional chemical insecticides, unsurprisingly, apply an environmental  
selection for resistant mosquitoes (Lam, 2013). One innovation in biological 
management is highlighted with the Wolbachia-based control. Ae. aegypti 
mosquitoes stably infected with strains of the obligate intracellular bacterium 
Wolbachia are resistant to DENV infection and are being tested in field trials in 
Australian (Ferguson et al., 2015). Noticeably, these antiviral effects rely on a 
complex tripartite system (the host, Wolbachia and virus) with the potential of 
unpredictable co-evolution (Johnson, 2015). Other novel control mechanisms 
include the development and release of a genetically modified Ae. aegypti strain 
carrying specific genes that abolish transmission cycle (Lam, 2013). However, 
these efforts have not eliminated disease transmission in countries where 
dengue is endemic (Hermann et al., 2015). 
To date, only one vaccine against dengue virus has been licensed. This 
vaccine consists of live-attenuated tetravalent chimeric dengue-yellow fever 
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vaccine strains. The DENV serotype-specific structural proteins are 
incorporated in a yellow fever virus 17D backbone (Weiskopf et al., 2014) 
(Nedjadi et al., 2015). Phase I and II trials conducted in adults in endemic and 
non-endemic regions have demonstrated a favorable safety profile and high 
immunogenicity. However, the vaccine was shown to be only effective in 
protecting against disease caused by DENV1 [61.2%], DENV3 [81.9%], DENV4 
[90.0%] but not DENV2 after single-dose injection (Lam, 2013). There are other 
vaccine candidates in development, yet none of them have been tested in Phase 
III trials. In summary, an imperfect vaccine alone is obviously not enough to 
curb dengue transmission (Christofferson & Mores, 2015). 
Molecular basis of DENV 
 
DENV has a positive-sensed, single-stranded, capped RNA genome. The 
10.7 Kb genome encodes 3 structural proteins (C, capsid protein; prM, 
precursor membrane protein; and E, envelope protein) and seven non-
structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) (Zhang, 
Sun, & Rossmann, 2015). During translation of the viral genome (+ssRNA), a 
single polyprotein is produced, and sequentially processed by cellular and viral 
proteases, releasing several structural and non-structural proteins as 
illustrated by Figure 2. The corresponding function of each of those proteins is 





Figure 2. Flavivirus genomic RNA and its translation product.  
(Hernandez, Brown, and Paredes 2014)  
Table 1. DENV proteins and their functions 
(Adapted from Nedjadi et al., 2015; Baharuddin et al., 2014; Tomlinson, 






Capsid (C)  Interacts with the genomic RNA to 




 An M protein precursor that primarily 
prevents premature rearrangement of the 
E protein under the mildly acidic 
conditions of the trans-Golgi prior to 
virion release 
 In the trans-Golgi network, the prM 
protein is cleaved by cellular furin to 




 Recognizes an unknown receptor on 
target host cells to induce viral uptake 
 Required for membrane fusion 






NS1  Involved in host immune response 
evasion 
NS2A  Poorly defined 




NS3  NTPase, helicase, and RTPase activities 
 
NS4A  Involved in induction of membrane 
rearrangement and/or autophagy 
response to viral infection of host cells 
NS4B  Anchor and target the replication complex 
to the endoplasmic reticulum (ER) 
membrane 
 Immune response antagonism 
NS5  RNA dependent RNA polymerase (RdRp) 
 Methyltransferase 
 Guanylyltransferase for mRNA capping 
 
DENV replication cycle 
DENV genome is enclosed by a capsid shell surrounded by a lipid bilayer 
envelope with envelope proteins (prM/E heterodimers) on the outer surface.  
The virus attach to target cells via the interaction of E protein (53KDa) with a 
variety of cellular receptors, including glycosaminoglycans (heparin sulfate), C-
type lectins (DC_SIGN [CD209] and the mannose receptor [CD206]), and 
immunomodulatory proteins (TIM/TAM receptors) (Diamond & Pierson, 2015). 
Upon attachment, receptor-mediated endocytosis is induced. The virus is 
internalized into the endosome, where proton-pumps on the endosomal 
membrane acidifying the endosome.  In response to lowered pH, prM/E 
heterodimers arranged into a trimer undergo conformational changes to form 
“spike”-like structures (Figure 3) and expose a hydrophobic fusion loop of the E 
protein (Figure 3. Red stars). This hydrophobic fusion loop inserts into the 
endosomal membrane, initiating a bending bridge between the endosomal and 
the virus membrane, leading to membrane fusion. Hence, the nucleocapsid is 
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released into the cytoplasm (Urcuqui-Inchima, Patiño, Torres, Haenni, & Díaz, 
2010). It is believed that the host membrane composition can play an important 
role in virus fusion (Rogers, Kent, & Rempe, 2015). Once in the host cytoplasm, 
the capsid thereby breaks apart, releasing the viral genome. The +ssRNA is 
translated, utilizing host machinery, into a single polyprotein. The polyprotein 
is further processed into structure proteins for assembly and non-structure 
proteins for viral genome replication. Genome replication occurs in virus–
induced membrane invaginations of the ER, coupled with encapsidation (Fischl 
W. and Bartenschlager R.; Apte-Sengupta, S. et al.; Chatel-Chaix & 
Bartenschlager). Once viral RNA associate with multiple copies of the C protein, 
viral genomes are packaged into nucleocapsids (NC), acquiring the prM/E 
heterodimers (Figure 2.A) containing ER membrane as immature particles into 
the lumen (Acosta, Kumar, & Bartenschlager, 2014). Immature particles will 
hijack the cellular canonical secretory pathway to egress (Chatel-Chaix & 
Bartenschlager). The slightly acidic pH (~5.8-6.0) of the trans-Golgi network 
(TGN) triggers dissociation of the prM/E heterodimers (Keelapang et al., 2004) 
(Figure 3.B). Viral particles mature further when furin (a trans-Golgi resident 
enzyme) cleaves the prM (approximately 21 KDa) into the pr peptide and the M 
proteins (8kDa) (Smit, Moesker, Rodenhuis-Zybert, & Wilschut, 2011) (Figure 
3.C). The pr peptide remains associated with the virion until it has been 
released from the cell (Figure 3.D). Both the prM protein and the pr peptide are 
believed to act as chaperones stabilizing the E protein to prevent a premature 
conformational rearrangement of the virion throughout the secretory pathway 






Figure 3. Structure of the dengue virion and conformations of the E 
protein during its maturation.  In supernatants of infected cells, the virus is 
found either as a mature or immature particle with a diameter of about 50 nm 
and 60 nm, respectively (Perera & Kuhn, 2008).  
 
Additionally, change from smooth to “spiky” conformation of virion 
(specifically DENV2) can not only be triggered by low pH, but by incubation at 
physiological temperature (37°C) (Zhang et al., 2015). Several studies suggest 
naturally occurring oscillation among ensemble of different structures, a 
phenomenon referred to as virus “breathing” (Guzman & Harris, 2015) (Dowd, 
DeMaso, & Pierson, 2015) (Zhang et al., 2015). The “breathing” structure might 
be able to explain the difficulty in deciphering mechanisms for ADE and the 
heterogeneity of pathogenesis.  
Antiviral target and development 
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Recent advances in drug discovery in combination with high-throughput 
screening (HTS) and structure-based drug design (SDD) have allowed the 
identification of drugable targets within the DENV replication cycle (Tomlinson 
et al., 2009) (Teixeira et al., 2014). Traditional direct-acting antiviral agents 
(DAA) target the enzymatic replication proteins including the protease-helicase 
(NS2B-NS3) (Luo, Vasudevan, & Lescar, 2015), components of replication 
complex (NS4B) (Xie, Zou, Wang, & Shi, 2015), and the viral polymerase/RdRp 
(NS5) (Malet et al., 2008).  Loss of function for any of these proteins will block 
virus propagation. Controversially, the suboptimal specificity of enzyme 
inhibitors or nucleoside analogs sometimes may occur at a risk for selection-
driven evolution of emergent drug-resistant viruses, which is further facilitated 
by the error-prone nature of RNA-dependent RNA polymerase (RdRp). To 
prevent the outgrowth of resistance, a novel strategy has been introduced to 
target  the hybridization of the targeted drug-susceptible and drug-resistant 
core proteins, defined as “dominant drug targets” (Mateo, Nagamine, & 
Kirkegaard, 2015.). 
In the light of molecular docking and stereochemistry studies, one can 
also design, or screen for, inhibitors that target critical regions of structural 
proteins, including the E protein β-OG pocket (Tambunan, Zahroh, Parikesit, 
Idrus, & Kerami, 2015) and the E protein stem region (Schmidt, Yang, & 
Harrison, 2010) (Figure 4.). By targeting the E protein, these inhibitors also 
inhibit other replication steps involving the E protein (i.e. endosomal escape), 
rather than prevention of entry itself.  The E protein stem region has a 
conserved amino acid sequence among all DENV serotypes and other 
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flaviviruses, providing another advantage as a drug target (Botting & Kuhn, 
2012). 
Drugs are also designed to target host factors essential for efficient viral 
replication. Examples mainly include glucosidases (Chang et al., 2012; 
Courageot, Frenkiel, Dos Santos, Deubel, & Desprès, 2000), kinases (de 
Wispelaere, LaCroix, & Yang, 2013; Smith et al., 2014), and the cholesterol 
biosynthesis pathway (Lee, Lin, Liao, & Lin, 2008). For example, Celgosivir, a 
clinically approved prodrug of castanos-permine, a product of the Moreton Bay 
chestnut tree (Castanospermum australae) proved to be an α-glucosidase 
inhibitor that prevent glycosylation of the NS1 protein (Botting & Kuhn, 2012). 
It has also been shown that α-glucosidase inhibitors strongly affects productive 
folding pathways of the prM and the E protein (Courageot et al., 2000). 
Unfortunately, the study failed to demonstrate clinical benefit in Phase 1b trails 
(Schapira, 2004).  
Figure 4. Sites of DENV E protein inhibition. (Botting & Kuhn, 2012.) 
The E protein domains are indicated by color; domain I in red, domain II in 
yellow and domain III in blue. The relative position of the M protein is indicated 
by green shading. The β-OG pocket and stem region (boxed) are common sites 
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of E protein targeting. The crystal structure of the E-protein indicates a ligand-
binding pocket that is filled with a detergent molecule, η-octyl-β-D-glucoside (β-
OG). This finding led to a number of docking studies to screening compounds 
for inhibition of E protein via the β-OG pocket(Baharuddin et al., 2014). 
Isolation of Chromobacterium. sp Panama (Csp_P) 
The symbiotic relationship between gut flora and their host organism has 
been widely studied (Hill, Sharma, Shouche, & Severson, 2014). The importance 
of this relationship, lead to an interest in the mosquito microbiota and its 
influence on the transmission of vector-borne pathogens. The potential 
application of microbes to control the transmission of vector-borne pathogens 
has been highlighted by several studies in the past decade. Based on the 
rationale that pathogens and microbes interact naturally in the mosquito 
midgut, an interest in understanding how bacteria influence the outcome of 
infection emerged. Previously, researchers in the Dimopoulos group isolated a 
Gram-negative, soil bacterium, Chromobacterium (Csp_P), from the midgut of 
Ae.aegypti mosquito in DENV-endemic areas in Panama (Figure 5.). When 
Csp_P is fed to mosquitoes prior to DENV infection, it can effectively colonize 
the mosquito midgut and significantly inhibit virus infection (Figure 6.) 
(Ramirez, Jose Luis et al.). Possible mechanisms underlying the compromised 
DENV infection are unknown, however, colonization with Csp_P induces 
mosquito innate immune system genes. In addition to the potential role of 
immune modulation, Csp_P appears to inhibit DENV replication in vitro, 
indicating a possible production of Csp_P-derived anti-DENV factors with 
transmission-blocking and therapeutic potential (Ramirez et al., 2014). 
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These findings lead to a couple of intriguing questions: what are the anti-
DENV factors being produced by Csp_P and how do they inhibit DENV 
replication in vitro. Here we described a study aiming to identify Csp_P-derived 
anti-DENV factors by using variety of classical methodologies. The experiments 
revealed that the anti-DENV factor is very likely to be bacterial secreted 
proteins that form a multiprotein complex. We also investigated the step of the 
DENV replication being affected by Csp_P-derived anti-DENV factors, and the 
mechanism of inhibition. Our in vitro and cell-free analysis favor a mechanistic 
model were Csp_P-derived anti-DENV factors inhibit DENV attachment to host 





Figure 5. Phylogenetic tree of the field and laboratory-reared Ae. 
aegypti cultivable midgut microbiota.  (Ramirez, Jose Luis et al.) 





Figure 6. Csp_P reduces mosquitoes' susceptibility to malaria and dengue 
infection. Antibiotic-treated adults were allowed to feed for 24 h on 1.5% 
sucrose containing Csp_P liquid culture at a final concentration of 
∼106 CFU/ml for Ae. aegypti. After introduction of Csp_P via the sugar 
meal, Ae. aegypti mosquitoes were given a blood meal that contained dengue 
virus. At 7 days after infection, midguts were dissected. Dengue virus titers 
were assayed in dengue-infected Ae. aegypti females by conducting standard 
plaque assays. Experiment were replicated at least three times with final 
samples sizes: PBS= 68, Csp_P = 45. Differences between treatments were 
assessed by Mann-Whitney test (*, p<0.05; ***, p<0.001). (Adapted from Ramirez 
et al. ) 
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MATERIALS AND METHODS 
Cell lines  
Baby hamster kidney cells (BHK-21 cells) were grown at 37°C in Dulbecco’s 
minimum essential medium (DMEM) containing 10% fetal bovine serum, 
penicillin, streptomycin and plasmocin. Aedes albopictus clone C6/36 cells 
(C6/36 cells) were grown at 32°C in Minimum essential medium with non-
essential amino acids and additives as above. 
Virus Stock 
C6-36 cells were used to propagate DENV-2 New Guinea C strain. C6-36 cells 
were incubated with DENV2 for 15 minutes on the shaker at room temperature 
following by 45 minutes at 32°C. After 6 days post infection (dpi), cell culture 
medium as well as cell lysis was collected. Supernatant containing virus was 
clarified by centrifugation at 1,500 – 2,000 g for 10 minutes. Virus stock was 
aliquoted and stored at -80°C for later use. 
Thermostability assay  
Csp_P supernatant was obtained by 72 hours Csp_P planktonic culture filtered 
through 0.22um membrane filter.  Supernatant was aliquot into 100ul per tube 
and incubated in the dry bath incubator at 37, 50, 70, 99 °C respectively for 1 
hour. Supernatant after heat treatment were then evaluated for their anti-
dengue activities by plaque reducing assay described as following.  
Protein extract preparation  
Csp_P supernatant was prepared as described above. Solid ammonium sulfate 
(AS) was slowly added to the supernatant to reach 30% saturation. After rapid 
stirring at 4°C for 1 hour, proteins (AS30%) were pellet down by centrifugation 
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at 10,000 g for about 20 minutes. The supernatant was carefully poured off and 
its volume was determined. Again solid AS was slowly added to the supernatant 
to reach 70% saturation. After rapid stirring at 4°C for 1 hour, proteins (AS70%) 
were pellet down by centrifugation at 10,000 g for about 20 minutes.  Protein 
pellet (AS70%) was gently resuspent in 0.1M Tris-HCl pH 7.2 buffer with 
protease inhibitors- EDTA free ( Burgess, 2009). Protein concentration was 
estimated by Nanodrop at 280nm. Protein resuspension was fractionated 
sequentially by ultrafiltration (UF) with 100, 50, 30, 10, 3 kDa membrane 
molecular weight cut off (MWCO). Each fraction was collected after 
centrifugation at 5000g for 10-20 mins. Protein concentration was roughly 
determined by Nanodrop at 280 nm. Recovery rate was calculated (>90%).  
Protein components of each fraction was visualized by SDS-PAGE gel with silver 
staining.  
Protein sequencing 
The 50-100kDa fraction of Csp_P AS70% resuspension was separated further 
by SDS-PAGE 4- 20% Tris-Glycine gel. The protein band of interest was 
identified by comparison with other fractions. Multiple bands of interest by 
running parallel sample were excised and poured from a Colloidal Blue Staining 
Kit (Invitrogen) stained gel. Gel pieces were washed in methanol and sent to the 
Johns Hopkins School of Medicine Mass Spectrometry and Proteomics Core 
Facility for identification using iTRAQ as described previously in detail (Pike A. 
et al.; 2015). MS/MS samples were analyzed using Mascot (Matrix Science, 
London, UK; version 2.5.1). Mascot was set up to search the 
160105_Chromobacterium_160501 database (unknown version, 91996 entries) 
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assuming the digestion enzyme trypsin. Scaffold (version Scaffold_4.4.8, 
Proteome Software Inc., Portland, OR) was used to validate MS/MS based 
peptide and protein identifications. Peptide identifications were accepted if they 
could be established at greater than 34.0% probability to achieve an FDR less 
than 1.0% by the Scaffold Local FDR algorithm. Protein identifications were 
accepted if they could be established at greater than 99.0% probability to 
achieve an FDR less than 1.0% and contained at least 2 identified peptides.  
Protein probabilities were assigned by the Protein Prophet algorithm. Amino 
acids sequences of identified proteins were further searched against 
Chromobacterium sp. Panama (Csp_P) database for unique hits.  
Plaque reduction inhibition assay 
BHK-21 cells or C6-36 cells were seeded at ~8.4 x 105 cells/well (24-well plate) 
and then incubated at 37 or 32 °C  overnight to reach 80~90% confluence. Prior 
to infection, 50 ul of DENV2 stock (NGC strain) was pre-incubated with each 
sample (1v:1v) at room temperature. After 1 hr, DENV2 and sample mixture 
was serially diluted (1:10) in DMEM medium. Cells were co-infected with 
DENV2-sample dilution for 15min at room temperature on the shaker followed 
by 45min at 32°C. ~1ml of overlay medium was added to each well. The plates 
were incubated for 5-6 days at 32°C under 5% CO2. BHK-21 cells were fixed 
and stained with 1% crystal violet in methanol/acetone (1v:1v) solution. C6-36 
cells were fixed with methanol/acetone (1v:1v) and blocked with 5% skim milk 
in PBS for 10 mins. Fixed C6-36 cells were incubated with mouse anti-DENV2 
4G2 antibody from ATCC (1:1000-1:2000) for 2 hrs at room temperature. After 
washed with PBS twice, C6-36 cells were incubated with goat anti-mouse IgG-
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HRP (1:1500) for 1.5 hrs at room temperature, following two rounds of PBS 
wash. Air dry the plate and add True Blue Peroxidase Substrate (KPL) to react 
for 5 mins on the shaker. The number of plaque forming units (PFU) per ml was 
determined.  
Immunofluorescence assay  
BHK 21 cells were seeded in 24-wells plate with cover slip in each well. After 
72hr growth at 37 °C, cells were infected with DENV-2 at a MOI of 10 in the 
presence of absence of Csp_P proteins for 1hr at 4 °C. Unbound virus are 
removed by washing 3 times with ice-cold PBS. Cells were fixed with 4% PFA for 
1 hr at 4 °C. Fixed cells were blocked with 0.5% BSA in PBS for 1 hr at room 
temperature, washed twice with PBS and incubated with m4G2 anti-DENV2 
antibody (ATCC) for 2 hrs at room temperature. Alexa Fluor 568 goat anti-
mouse IgG (Invitrogen) was used as secondary antibody. Beta-actin was stained 
with Alexa Fluor 488 Phalloidin (Invitrogen). Nuclei were stained with DAPI. 
Samples were mounted by ProLong Gold antifade reagent. Fluorescence 
analysis was performed on a Leica DM 2500 fluorescence microscopy (Vervaeke 
et al., 2013).  
Time course studies on the anti-DENV activity  
BHK-21 cells were seeded at ~8.4 x 105 cells/well (24-well plate) and then 
incubated at 37 overnight to reach 80~90% confluence. Csp_P supernatant 
were added under the following conditions: 
Pre-infection treatment: BHK-21 cells were treated with serial dilutions (1:10) of 
Csp_P supernatant (100ul/well). After 1 hour incubation at 37 °C, the cells 
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were washed twice with PBS and infected with 100ul/well of DENV2 at the 
same serious dilution for 1 hour at 37 °C. Overlay medium was added and the 
viral titer was determined 5 days post infection using plaque reduction 
inhibition assay.  
Co-infection treatment: BHK-21 cells were treated with serial dilutions (1:10) of 
Csp_P supernatant and DENV2 (1v:1v) in 100ul/well. After 1 hour incubation 
at 37 °C, overlay medium was added and the viral titer was determined 5 days 
post infection using plaque reduction inhibition assay. 
Post-infection treatment: BHK-21 cells were infected with serial dilutions (1:10) 
of DENV2 (100ul/well) for 1 hour. The cells were washed with PBS and treated 
with Csp_P supernatant (100ul/well) at the same serious dilution for 1 hour at 
37°C. Overlay medium was added and the viral titer was determined 5 days 
post infection using plaque reduction inhibition assay (Schmidt et al., 2012). 
Virus attachment assay  
Pre-attachment: BHK-21 cells in 24-well plates and reagents were cooled to 
4°C. Virus and Csp_P extract were incubated at 4°C for 1h, then transferred to 
chilled BHK-21 cells and incubated for another 1h at 4 °C. After incubation, cell 
monolayers were washed 3X with cold PBS, overlay medium was added and 
cells were incubated at 37 °C for 5 days before fixing and staining for plaque 
forming unit.  
Post-attachment: BHK-21 cells in 24-well plates and reagents were cooled to 
4°C. Virus was added to cells and allowed to bind for 1h at 4°C. Unbound virus 
was washed off by washing twice with cold PBS. Csp_P extract was then added 
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to virus bound cells and incubated for 1h at 4°C. Following incubation, cell 
monolayers were washed once with cold PBS. Overlay medium was added and 
cells were incubated at 37 °C for 5 days before fixing and staining for plaque 
forming unit (Fibriansah et al., 2014 ). 
Cell viability assay by trypan blue staining 
BHK-21 cell suspension (1x105 to 2x105 cells/ml) was prepared in DMEM 
without FBS. 50ul of suspension was put in each Eppendorf tube, mixed with 
10ul of sample or control (10% DMSO). Tubes were incubated at 37°C for 1 
hour. 12ul of 0.4% Trypan Blue Stain (Invitrogen) was added to each tube and 
incubate for 5 minutes. 10ul of cell suspension from each tube was harvested 
and added to hemacytometer (Thermos). Cells were counted in the microscope 
under a 20X objective.  
Western blot analysis for Csp_P proteins treatment  
Solutions of sample and control were prepared as follows:  
A: 50ul of DENV2 stock + 50ul of 0.1M Tris-HCl buffer;  
B: 50ul of DENV2 stock + 50ul of Csp_P protein suspension;  
C: 50ul of DENV2 stock + heat inactivated Csp_P protein suspension;  
D: 50ul of MEM medium + 50ul of Csp_P protein suspension. 
After 1 hour incubation at room temperature, each solutions were added to 
individual filtration tubes (MWCO= 100kDa) filled with 4ml of 1M Tris-HCl 
pH7.2 buffer (higher salt concentration to reduce non-specific binding). 
Centrifuged for 15 mins at 5,000 g. Concentrated sample and control after 
treatment were collected and applied on SDS-4-20% polyacrylamide gels. 
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Protein bands were later on transferred to a nitrocellulose membrane, following 
overnight blocking at 4°C in 5% silk milk-PBST. Dengue2 E proteins were 
probed by anti-E rabbit polyclonal antibodies (1: 2,000 dilution and anti-rabbit 
HRP (1:20,000 dilution) was added for 1 hour incubation. 3 times of washing 
with PBST between each step. Signals were detected with Amersham ECL kit.  
Statistical Analysis   
Data from plaque assays were analyzed using the GraphPad Prism statistical 
software package (Prism 5; GraphPad Software, Inc., San Diego, CA). Unpaired 
t-test (two-tailed) was conducted on the mean value of triplicates from least two 
individual biological replicates. Statistical significance numerated by p-value is 





Effect of Csp_P culture supernatant on in vitro DENV replication 
Previously, Ramirez et al. have shown the in vitro anti-DENV activity of 
Csp_P liquid culture. In their study, Csp_P bacterial preparation (unfiltered) was 
mixed with DENV2 virus stock (1v: 1v) and incubated at room temperature for 
45 min. This mixture was then filtered before anti-DENV measurement. Here we 
assessed if Csp_P culture supernatant (Csp_P sup) without live bacteria could 
still inhibit DENV2 replication. Csp_P bacterial preparation (filtered) was mixed 
with DENV2 virus stock (1v:1v) and incubated at the same conditions. DENV2 
replication in both BHK21 cells (mammalian) and C6/36 cells (mosquito) was 
inhibited (P value <0.0001 in BHK21 cells, P value=0.0003 in C6/36 cells) 
compared to the LB control (Figure.7 upper). A similar level of anti-DENV2 
activity, in both cell lines, indicates that the target of the Csp_P-derived factor(s) 
could be viral proteins, RNA or host factors conserved across species (Haridas 
et al., 2013). In crystal violet staining of Csp_P culture supernatant treated 
BHK21 cells did not result in a significant cell detachment, while virus infection 
was inhibited (Figure 7. lower left). These results suggest that, under the 
inhibitory concentration of Csp_P culture supernatant, the viability of BHK21 
cells is not significantly affected. However, additional experiments are required 




Figure 7. Csp_P supernatant inhibits DENV2 replication in BHK21 cells 
and C6-36 cells. Prior to infection, DENV2 stock was incubated with Csp_P sup 
for 1 hour at room temperature. BHK-21 cells were then infected with Csp_P-
DENV2 (at MOI=0.01) for 5 days at 37° C and stained with crystal violet 
solution (each empty plaque represent an infectious colony). Similar 
experiments were done using C6-36 cells, except DENV2 infectious colonies in 
C6-36 cells (MOI=0.01) were immunostained with anti-DENV2 m4G2 antibody 
(empty space represent non-infectious cells). (A) Strong inhibition of DENV2 
conferred by Csp_P supernatant was observed in both BHK21 cells (P < 0.0001) 
and C6/36 cells (P = 0.0003). (B) Representative plaque assay is shown. Error 
bars represent the standard error of the mean from 3 biological replicates with 
technical triplicates. Statistical analysis was performed using unpaired t test 
(***P < 0.001). 
The Csp_P –produced anti-DENV has protein-like properties  
As shown above, Csp_P culture supernatant is able to inhibit DENV 





DENV factors from this supernatant, we first assayed the anti-DENV activity in 
different fractions of the Csp_P supernatant. We observed appreciable anti-
DENV activity of the protein fraction (Asp70%50-100K), which precipitated by 
ammonium sulfate at a saturation of 70% (Asp70%), with molecular weights 
ranging from 50 to 100kDa.  
Thermal stability of Csp_P supernatant 
There are a variety of molecules in a bacterial culture supernatant, such 
as proteins, lipids, polysaccharides, nucleic acids and other small molecules 
(secondary metabolites). Among them, secondary metabolites often harbor 
aromatic rings that stabilize their structures at high temperatures. On the 
contrary, macromolecules (especially proteins) are unstable at temperatures 
between 40-80°C (Bischof & He, 2005). To determine the thermostability of anti-
DENV factors, samples of Csp_P culture supernatant were heat-treated for 1 
hour at 37, 50, 70, and 99 °C, and then pre-incubated with DENV for 1 hour 
prior to virus titer determination through plaque assays. As interpreted by the 
observed changes in DENV titers, the anti-DENV factors within the Csp_P 
culture supernatant were stable up to 50°C, but were inactivated at a 70°C 
treatment for 1h (Figure 8). This result indicates a heat-sensitive factor-likely a 




Figure 8. Anti-DENV activity of Csp_P supernatant is destroyed at 
temperatures higher than 70 °C. Samples of Csp_P sup and LB control were 
heat-treated for 1 hour at different temperatures (37, 50, 70, 99°C). DENV2 
stocks were pre-incubated with heat-treated Csp_P sup and LB control for 1 
hour. Anti-DENV activity of each heat-treated sample of Csp_P sup was tested 
by plaque assay on BHK-21 cells, and compared to that of paralleled LB control 
with the same treatment. Upon 1 hour heat-treatment at over 70°C, Csp_P sup 
confers no significant inhibition to DENV2. No plaque was detected in plaque 
assays using heat-treated (at 37 and 50°C) Csp_P sup, thus no statistical 
analysis could be done with these two groups. Error bars represent the 
standard error of the mean from 3 biological replicates with technical 
triplicates. Statistical analysis was performed using unpaired t test (ns, not 
significant). 
 Bioseparations of Csp_P-derived anti-DENV factors 
To verify the protein-like property of anti-DENV factors, we measured the 
anti-DENV activity of Csp_P a secreted protein extract. Our strategy for 
extracting proteins from the Csp_P culture supernatant was precipitation: the 
solubility of proteins decreases with increased concentration of the precipitant 
in the aqueous phase. As a classical precipitant, ammonium sulfate (AS) is 
stabilizing protein structures, is soluble and relatively inexpensive (Burgess, 
2009). Although we were also able to extract Csp_P proteins by TCA-acetone 
(another classical precipitation method), we noticed an irreversible denaturation 



































to AS precipitation). Upon AS precipitation at a saturation of 70%, Csp_P 
proteins were precipitated, pelleted, resuspended in a 0.1M Tris-HCl pH7.2 
buffer and then desalted by ultracentrifuge. The remaining Csp_P supernatant 
was desalted and concentrated by ultra-centrifuge. After pre-incubation of 
DENV2 with the pellet resuspension and supernatant, the anti-DENV activity of 
both fractions was tested by plaque assays.  We observed a dramatic anti-DENV 
activity in Csp_P proteins pellet (Figure 9. pellet) but not in the supernatant 
(Figure 9. sup). The anti-DENV activity of Csp_P proteins was confirmed by a 
dose-response relationship between the concentrations of the AS 70% protein 
suspension (ASp70%) and its anti-DENV activity measured by plaque assay 
(Figure 10).  
 
Figure 9. The anti-DENV activity of Csp_P proteins. Csp_P proteins (Pellet) 
were precipitated by ammonium sulfate (AS) at the saturation of 70% and 
resuspent in 0.1M Tris-HCl pH7.2 buffer. The supernatant left behind (Sup) 
was desalted and concentrated. DENV2 stocks were pre-incubated with either 
fraction (Pellet/ Sup) or LB control for 1 hour. Anti-DENV activity of each of 
Csp_P fractions was tested by plaque assay on BHK-21 cells and was compared 
to that of LB control. Significant inhibitory effect on DENV2 was observed from 
Csp_P protein pellet (P = 0.0083) rather than sup, measured by plaque assay on 






























biological replicates with technical triplicates. Statistical analysis was 
performed using unpaired t test (***P < 0.001; ns, not significant). 
 
 
Figure 10. Dose-dependent anti-DENV activity of Csp_P proteins (ASp 
70%). Serially diluted Csp_P proteins (resuspension of Csp_P proteins pellet, 
6.01mg/ml quantified by BCA assay) were pre-incubated with DENV2 stocks, 
anti-DENV activities were measured by plaque assay on BHK21 cells. As fold of 
dilution increase from 1:10 to 1:100, anti-DENV activity conferred by Csp_P 
proteins (Asp70%) was gradually decreased. Error bars, represent the standard 
error of the mean from 3 biological replicates with technical triplicates. 0.1M 
Tris-HCl pH 7.2 buffer was used as control and for series dilution. 
Assessing the size of the anti-DENV factor 
Further fractionation of the AS70% pellet was carried out using 
ultrafiltration with different molecular weight cut off (MWCO) membranes, 
ranging from 100kDa to 3kDa. The resuspended AS70% pellet was thereby 
divided into 5 fractions: >100kDa, 100-50kDa, 50-30kDa, 30-10kDa and 10-
3kDa fraction. The 100-50kDa fraction contained the anti-DENV activity of the 
AS70% pellet (Figure 11.A) (P = 0.0015) compared to that of the AS70% pellet (P 
= 0.0021). However, no difference in protein composition between the fractions 
was observed by 1D SDS-PAGE analysis. In fact, smaller proteins (with mass 
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lower than the membrane MWCO) were also enriched in each fraction along 
with target proteins (with masses higher than membrane MWCO) (Figure 11.B). 
One possible reason could be protein-protein interactions that naturally exist. It 
could also be an artifact of ultrafiltration: the retained larger proteins creating 
an extra layer that retained the smaller proteins. Current results are however 
supporting the hypothesis that observed anti-DENV activity is associated with a 
secreted multiprotein complex derived from Csp_P, within the molecular weight 








Figure 11. Csp_P secreted proteins in 50 -100KDa are associated with anti-
DENV activity. (A) Csp_P proteins extracted from ammonium sulfate 
precipitation (Pellet) was further separated into 5 fractions with different protein 
mass. Each fraction was adjusted to approximately the same protein 
concentration (determined by BCA assay) for further analysis. Anti-DENV 
activity of each fraction was tested by plaque assay on BHK21 cells. Within 5 
fractions, only >100kDa (P = 0.0154) and 100-50kDa (P = 0.0015) fraction 
restored anti-DENV activity from ASp70% pellet (P = 0.0021), compared to 
buffer control respectively. DENV2 preincubated with 100-50K fraction [(8.3 ± 
2.6) x104 pfu/ml] has lower viral titers compared to one preincubated with 
ASp70% pellet [(2.5 ± 0.53) x105 pfu/ml].  Error bars represent the standard 
error of the mean from 3 biological replicates with technical triplicates. 
Statistical analysis was performed using unpaired t test (*P < 0.1; **P < 0.01; 
***P < 0.001; ns, not significant). (B) ASp 70% pellet and its 5 fractions were 
subjected to SDS-PAGE gel and silver stained. Arrow: hypothesized proteins 
associated with anti-DENV activity.  
Proteomic analysis of Csp_P secreted proteins 
Only one major protein band (Figure 11B, arrow) within the 100-50 kDa 
molecular weight was found in 100-50 kDa fraction by silver-stained SDS-PAGE 
analysis. Hence, we hypothesized that this protein band (Figure 11B, arrow) 
would be associated with most of the anti-DENV activity. We performed 
proteomic analysis of this protein band (~55kDa). iTRAQ labeling methodology 
was used in LC/MS/MS to fragment and analyze its potential identity. We 
identified 557 peptide spectrums that matched to 370 peptides that, in turn, 
mapped to 45 proteins using the 160105_Chromobacterium_160501 database 
(including multiple strains). These proteins were assigned putative names and 
functions through a BLASTp analysis against the Chromobacterium Csp_P 
genome, yielding 33 unique proteins (Table 2). After applying two additional 
filters; molecular weight between 50 to 64 kDa and the presence of signal 
peptides (analyzed by signal P 4.1)/non-classically secreted motif (predicted by 
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SecretomeP 2.0a), we finally obtained the following 7 Csp_p protein candidates: 
bifunctional metallophosphatase 5-nucleotidase, peptidase m4, phopq-activated 
pathogenicity related family protein, chitinase, tail protein, pkd domain 
containing protein, and fad-liked oxidase (Table 2. shading). Further 
experiments, either using mutagenesis or overexpressing protein candidates 
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Mechanism of Csp_P derived anti-DENV activity 
In previous studies we have shown a potent anti-DENV activity carried by 
Csp_P secreted proteins. The anti-DENV activity was consistently measured by 
plaque assays in which we pre-incubate Csp_P derived samples and DENV2 for 
1 hour prior to infection. However, the mechanism by which the Csp_P secreted 
factors inhibit DENV replication in vitro was unknown. We modified the plaque 
assay in a way that would allow us to identify the stage at which DENV 
replication is inhibited by Csp_P factors. 
 Studies on the infection-stage specificity of the anti-DENV activity 
To characterize the infection stage specificity of the anti-DENV activity 
conferred by Csp_P secreted factors, the Csp_P supernatant was either added to 
the BHK21 cells prior to infection, or at the time of infection, or post infection, 
or incubated with DENV for 1 hour prior to infection. Anti-DENV activity of 
Csp_P supernatant in each sample was measured by plaque assays (Figure 12). 
Our results showed that pre-treatment of BHK21 cells with Csp_P supernatant 
has no effect on DENV replication, suggesting the target of Csp_P factors is less 
likely to be a host factor. Interestingly, dramatic anti-DENV activity was 
observed when we pre-incubate DENV with Csp_P supernatant for at least 1 
hour prior to infection (Figure 12. pre-incubation), however, when we co-
exposed cells with DENV and Csp_P supernatant, we didn’t observe any anti-
DENV activity (Figure 12. co-infection). One possible cause of this discrepancy 
could be the inhibition kinetics of Csp_P factors is affected by interaction 
between outer components of the virion and the cellular receptor. To clarify this 
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we arrested DENV infection at the attachment step and extended our analysis 
on the inhibitory effect of Csp_P factors.  
 
Figure 12.  Time course studies on the anti-DENV activity. Csp_P 
supernatant were added to treat BHK21 cells or DENV2 in different orders. Pre-
infection: BHK21 cells were treated with Csp_P supernatant for 1 hour, washed 
with PBS and infected with DENV2. Co-infection: Csp_P supernatant was mixed 
with DENV2, series diluted, and co-infect BHK21 cells for 1 hour. Post-
infection: BHK21 cells were infected with DENV2 for 1 hour, washed with PBS, 
and treated with Csp_P supernatant for 1 hour. Preincubation: DENV2 was 
preincubated with Csp_P supernatant for 1 hour prior to infection. Mixture was 
series diluted and infect BHK21 cells for 1 hour. DENV2 titers were measured 
by plaque assay on the 5 th day post infection. DENV2 replication was not 
significantly affected by pre-infection (P = 0.8749)/co-infection (P = 
0.3634)/post-infection (P = 0.4063) treatment with Csp_P supernatant. In 
contrast, DENV2 replication was dramatically inhibited by pre-incubation with 
Csp_P supernatant prior to infection, as no plaque being detected by plaque 
assay. Error bars represent the standard error of the mean from 2 biological 
replicates with technical triplicates. Statistical analysis was performed using 
unpaired t test to compare difference between Csp_P supernatant treatment 
and mock treatment with DMEM medium.  
 Virus attachment assay 
Cellular attachment of the virus particles is the first step that initiates virus 
entry and all the following steps necessary to unpack viral genome. Here we 




























mediated endocytosis through a low temperature. By incubating DENV with 
pre-chilled cells at 4°C, we could arrest DENV infection at the attachment step 
and analyze the effect of Csp_P proteins on DENV without interference from 
receptor binding. In the pre-attach assay, we incubated DENV with Csp_P 
proteins for 1 hour at room temperature. After incubation, we exposed DENV-
Csp_P proteins to pre-chilled cells at 4°C for cellular attachment. Unbound 
virions were washed off after 1 hour attachment. Attached virions were allowed 
to complete infection at 37°C. In the post-attachment assay, DENV virions were 
exposed to pre-chilled cells at 4°C for 1 hour attachment. After extensive wash, 
Csp_P proteins were added to treat attached-virions for 1 hour at 4°C. After 
another round of wash, attached virions were allowed to complete infection at 
37°C. Our results showed a significant decrease (P = 0.0002) in DENV titers as 
we treated DENV with Csp_P proteins before viral attachment (Figure 13. Pre-
attach). On the contrary, Csp_P proteins failed to inhibit DENV replication when 
attachment had already occurred (Figure 13. Post-attach). Thus, Csp_P proteins 
are most likely inhibiting the cellular attachment step of DENV.   
 
Figure 13. Attachment assay. Csp_P proteins/control buffer was added as 























hour treatment, cells were moved to 37°C in order to complete endocytosis. 
DENV2 titers were measured by plaque assay on the 5th day post infection. 
DENV2 replication was dramatically inhibited by treatment with Csp_P proteins 
prior to attachment (P = 0.0002) rather than post attachment (P = 0.2060). 
Error bars represent the standard error of the mean from 3 biological replicates 
with technical triplicates. Statistical analysis was performed using unpaired t 
test to compare difference between Csp_P proteins treatment and mock 
treatment with control buffer. 
 
We next sought to validate this result by immunofluorescence 
microscopy. Attachment of DENV virions to a monolayer of BHK-21 cells were 
arrested at 4°C, fixed and stained by anti-E protein. The effect of preincubation 
with Csp_P proteins on DENV attachment was visualized under the microscope. 
Consistent with result from attachment assay, preincubation with Csp_P 
proteins dramatically inhibited DENV attachment to BHK21 cells, leading to 




Figure 14. Csp_P proteins abolish DENV2 attachment to BHK21 cells. Cell 
control: BHK 21cells were fixed and stained with DAPI (nucleus: blue), 
Phalloidin (cell actin: green) and anti-DENV2 E protein (red) for microscopy. 
Virus control:  DENV2 were added to BHK21 cells (MOI=10) for 1 hour 
attachment at 4°C. After twice of PBS washes, DENV2-bounded cells were fixed 
and stained for microscopy. Csp_P proteins treatment: DENV2 treated with 
Csp_P proteins for 1 hour were added to BHK21 cells (MOI=10) together for 1 
hour attachment at 4°C. DENV2 with normal attachment was detected in Virus 
control (red), while treatment with Csp_P proteins effectively abolished DENV2 
attachment.  
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 Effect of Csp_P proteins treatment on DENV integrity 
The data described earlier showed that a 1 hour exposure of DENV to Csp_P 
proteins can effectively inhibit viral attachment of DENV. Given that the E 
protein of DENV essentially mediates viral attachment and entry into host cells, 
it raised a question whether the DENV E protein is still functional or not after 
treatment with Csp_P proteins. To address this question, DENV virions treated 
with Csp_P proteins were subjected to western blot using rabbit anti-DENV2 
envelope polyclonal antibodies. As illustrated in Figure 15, treatment of DENV 
with Csp_P proteins resulted in a significant loss of the E protein, compared to 
the untreated DENV virions. More importantly, a cleaved fragment (about 
17kDa) of DENV E protein was detected in Csp_P proteins treated virions (here 
we used a rabbit/IgG targets to a region within amino acid 1 and 495 of DENV 
E protein). None of Csp_P proteins has cross-reactivity with the used antibodies 
(data not shown).  Based on our current results, one possible explanation for 
the abolished viral attachment could be enzymatic cleavage of DENV E protein 




Figure 15. Csp_P proteins treatment leads to loss of dengue E protein. 
DENV2 virions were treated with Csp_P proteins or mock-treated with control 
buffer in Eppendorf tubes. After 1 hour incubation at room temperature, 
samples were clarified by 100kDa membrane filter at 5000g for 15mins and 
subjected to immunoblotting with a rabbit polyclonal antibody against dengue 
type 2 Envelope (E) protein. Arrow: E proteins in DENV2 virions. DENV2 treated 
with Csp_P proteins show decreased signal intensity for E proteins. In control 
experiments, DENV2 alone can be detected by anti-E as illustrated by arrow on 




Limitations of the current study 
Further separation of Csp_P 50-100kDa protein fraction should be 
conducted using a combination of chromatography methods: for example by 
size-exclusion-chromatography followed by ion-exchange-chromatography. We 
tried to use a DENV affinity column to capture the putative DENV binding 
partner, contained in the Csp_P secretome, however, the immobilization of 
DENV virions on a stationary phase presented technical difficulties. We also 
failed to validate a possible association between Csp_P secreted proteins and 
DENV virions using a co-immunoprecipitation assay, presumably due to the 
cleavage of virion surface proteins. Additionally, most of our results were solely 
based on in vitro plaque assays, while they would have been more robust  if 
based on more than one methodology for antiviral measurement (Teixeira et al., 
2014).    
Future directions  
Our proteomic analysis for the identification of the Csp_P-derived 
factor(s) that mediate DENV inhibition will be a major focus of future work. 
Given the observed cleavage of the DENV E protein by a Csp_P–derived factor 
we will first focus on Csp_P proteases (mostly metalloproteases). Modern 
bioinformatics tools can be used to perform protein cleavage sites prediction 
based on the function of enzyme in interest. However, we certainly need to 
validate the kinetics of enzymatic reaction between the putative Csp_P -
produced protease and DENV E protein. Nevertheless, a purified or expressed 
protease is required for these studies. 
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A fad-linked oxidase that was also contained in the Csp_P secreted 
protein extract shows sequence similarity to a cholesterol oxidase (CHOD) 
produced by other strains of Chromobacterium. CHODs are found exclusively in 
bacteria and are able to catalyze the oxidation and isomerization of cholesterol 
(Reiss, Faccio, Thöny-Meyer, & Richter, 2014). One study has shown that 
cholesterol depletion inactivates the Xenotropic murine leukemia virus-related 
virus (XMRV, an enveloped virus) and leads to viral envelope protein release 
from virions (Tang, George, Taylor, & Hildreth, 2012). In our case, we observed 
a significant decrease in the amount of the E protein on DENV virions upon 
Csp_P protein extract treatment, along with abolished infectivity. A study by 
Carro & Damonte, 2013 showed that preincubation of virions with a cholesterol 
extracting compound significantly reduced virus infectivity in a dose-dependent 
manner. Parallel to our results, they also demonstrated no effect on DENV 
infection when cells had been pre-treated with the same compound. Several 
studies have indicated a stringent requirement for membrane components, 
especially with respect to the percent of cholesterol and lipids, at various steps 
of the flavivirus life cycle (Acosta et al., 2014)(Mosso, Galván-Mendoza, Ludert, 
& del Angel, 2008) (Lee et al., 2008). For example, Umashankar et al., 2008 
showed that the removal of cholesterol from mammalian cells will inhibit DENV 
production whereas studies with insect cells demonstrated that cholesterol is 
not required for DENV entry and membrane fusion. This could be explained by 
the intrinsic differences in membrane cholesterol-levels between different cell 
lines, and differences in the required cholesterol content for DENV propagation.  
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A purification strategy for microbial-derived CHOD has been previously 
reported in Yagi, 1973, and more recently by Doukyu, Shibata, Ogino, & 
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